Canland Health Announces Non-Brokered Private Placement

VANCOUVER, BC / ACCESSWIRE / October 29, 2019 / Canland Health Corp. (the “Company”) today announced that it intends to arrange the placement of up to 2,120,000 common shares priced at $0.25 per common share for total gross proceeds of up to $530,000 (the “Offering”). Proceeds from the Offering and prior financings shall be used for investigating project acquisitions and general corporate purposes. The Offering is subject to regulatory approval and all securities to be issued pursuant to the Offering are subject to a four-month hold period under applicable Canadian securities laws.

For further information regarding this news release contact:

C.K. Cheung, CEO
Tel: 416 904 1478

On behalf of the Board of Directors
CANLAND HEALTH CORP.

THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AND DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO SELL ANY OF THE SECURITIES DESCRIBED HEREIN IN THE UNITED STATES. THESE SECURITIES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE UNITED STATED SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERSONS UNLESS REGISTERED OR EXEMPT THEREFROM.

SOURCE: Canland Health Corp.

View source version on accesswire.com:
https://www.accesswire.com/564593/Canland-Health-Announces-Non-Brokered-Private-Placement

Staff

Recent Posts

GE HealthCare Announces Cash Dividend for First Quarter of 2024

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a…

1 hour ago

GE HealthCare to Feature Latest Technologies in Interventional Radiology Focused on Precision Care at SIR 2024

Multi-modality showcase brings hands-on experience to care delivery for a wide range of vascular diseases…

1 hour ago

Smartsheet Names Katie Rooney to Board of Directors

Experienced global CFO adds depth in financial strategy and operating excellence to Smartsheet boardBELLEVUE, Wash.--(BUSINESS…

1 hour ago

The Centers for Medicare & Medicaid Services Revise National Coverage Determination for Stem Cell Transplantation

The Centers for Medicare & Medicaid Services revise the National Coverage Determination of allogeneic hematopoietic…

2 hours ago

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash. (March…

3 hours ago